TRACON Pharmaceuticals (NASDAQ:TCON) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

Shares of NASDAQ:TCON opened at $0.03 on Tuesday. The company’s fifty day moving average is $0.04 and its two-hundred day moving average is $0.28. TRACON Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $14.75. The stock has a market capitalization of $109,802.00, a price-to-earnings ratio of 0.01 and a beta of 1.37.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.